Induction of p16 at sites of cartilage invasion in the SCID mouse coimplantation model of rheumatoid arthritis.код для вставкиСкачать
CONCISE COMMUNICATIONS 3. Passas CM, Wong RL, Peterson M, Testa MA, Rothfield A. A comparison of the specificity of the 1971 and 1982 American Rheumatism Association criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1985;28:620–3. 4. Yokohari R, Tsunematsu T. Application, to Japanese patients, of the 1982 American Rheumatism Association revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1985;28:693–8. 5. Hochberg MC, for the Diagnostic and Therapeutic Criteria Committee of the American College of Rheumatology. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997;40:1725. 6. Trimble RB, Townes AS, Robinson H, Kaplan SB, Chandler RW, Hanissian AS, et al. Preliminary criteria for the classification of systemic lupus erythematosus (SLE): evaluation in early diagnosed SLE and rheumatoid arthritis. Arthritis Rheum 1974;17:184–8. 7. Somogyi L, Cikes N, Marusic M. Evaluation of criteria contributions for the classification of systemic lupus erythematosus. Scand J Rheumatol 1993;22:58–62. 8. Manu P. Receiver operating characteristic curves of the revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1983;26:1054–5. 9. Edworthy SM, Zatarain E, McShane DJ, Bloch DA. Analysis of the 1982 ARA lupus criteria data set by recursive partitioning methodology: new insights into the relative merit of individual criteria. J Rheumatol 1988;15:1493–8. 10. Levin RE, Weinstein A, Peterson M, Testa MA, Rothfield NF. A comparison of the sensitivity of the 1971 and 1982 American Rheumatism Association criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1984;27:530–8. 11. Merkel PA, Chang Y, Pierangeli SS, Convery K, Harris EN, Polisson RP. The prevalence and clinical associations of anticardiolipin antibodies in a large inception cohort of patients with connective tissue diseases. Am J Med 1996;101:576–83. 12. Tsutsumi A, Ichikawa K, Atsumi T, Matsuura E, Koike T, Krilis SA. Use of various methods for anticardiolipin detection in the updated American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus: comment on the letter by Hochberg [letter]. Arthritis Rheum 1998;41:1326–7. 13. Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette J-C, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999;42: 1309–11. 14. Exner T. Conceptions and misconceptions in testing for lupus anticoagulants. J Autoimmun 2000;15:179–83. 15. Jacobsen EM, Barna-Cler L, Taylor JM, Triplett DA, Wisloff F. The evaluation of clotting times in the laboratory detection of lupus anticoagulants. Thromb Res 2001;104:275–82. 16. Pierangeli SS, Stewart M, Silva LK, Harris EN. An antiphospholipid wet workshop: 7th International Symposium on Antiphospholipid Antibodies. J Rheumatol 1998;25:156–60. 17. Abu-Shakra M, Gladman DD, Urowitz MB, Farewell V. Anticardiolipin antibodies in systemic lupus erythematosus: clinical and laboratory correlations. Am J Med 1995;99:624–8. DOI 10.1002/art.11045 Induction of p16 at sites of cartilage invasion in the SCID mouse coimplantation model of rheumatoid arthritis Rheumatoid arthritis (RA) is the most common type of chronic inflammatory arthritis in humans. It is characterized by synovial hyperplasia and pathologic immunologic phenom- 2069 ena mediating progressive joint destruction (1). There is increasing evidence that activated RA synovial fibroblasts (RASF) are key players in the process of joint destruction (2). However, the mechanisms of activation of RASF are not completely understood. The tumor suppressor protein p16 inhibits the binding of cyclin-dependent kinases 4 and 6 with the D cyclins. Thereby, it blocks the phosphorylation of the retinoblastoma (Rb) protein. Unphosphorylated Rb does not release E2F and does not induce G1 entry into the cell cycle (3). Therefore, p16 is a cell cycle inhibitor mediating G1 arrest. Since it is encoded on human chromosome 9p in the INK4a/ARF locus, p16 is also called p16INK4a. It is worth noting that this genetic region is frequently mutated in patients with cancer (4). Interestingly, Taniguchi et al demonstrated that RASF were different from osteoarthritis synovial fibroblasts (OASF), normal synovial fibroblasts (NSF), and skin fibroblasts in terms of regulation of the p16INK4a tumor suppressor gene (5). Synthesis of p16INK4a was enhanced by serum starvation, ␥-irradiation, and induction of senescence and resulted in irreversible growth arrest. In contrast, expression of p16INK4a was not increased by these treatments, nor was recovery of proliferation after addition of serumcontaining medium prevented in OASF or embryonic lung fibroblasts. Intriguingly, administering p16 by adenoviral gene transfer to rats with adjuvant-induced arthritis and to mice with collagen-induced arthritis resulted in reduction of synovial cell hyperplasia and of mononuclear cell infiltration (5,6). The role of the tumor suppressor protein p16INK4a in RA is not well defined. Questions remain regarding the expression pattern of p16INK4a in RA tissues, which cell types express it, and the role of p16INK4a in joint destruction, specifically at sites of cartilage invasion. Therefore, in the present study we investigated the expression of p16INK4a in RA synovial tissues and in control tissues by immunohistochemistry analysis. Levels of p16 messenger RNA (mRNA) and protein in cultured RASF were investigated by real-time polymerase chain reaction (PCR) and by immunofluorescence, respectively. Finally, we explored whether RASF express p16INK4a at sites of cartilage invasion in the SCID mouse coimplantation model of RA. Synovial tissue specimens were obtained from RA (n ⫽ 13), OA (n ⫽ 2), and normal synovia (n ⫽ 1) at the time of synovectomy, joint replacement, or trauma surgery. Samples were fixed in 4% neutral buffered formalin for 6–8 hours, dehydrated, and then embedded in paraffin using an automated tissue processor. All RA patients fulfilled the American College of Rheumatology (formerly, the American Rheumatism Association) criteria for diagnosis of the disease (7). Synovial fibroblasts were obtained by enzymatic digestion of synovial tissue from RA patients (n ⫽ 10) and normal synovial tissue (n ⫽ 1) and cultured as previously described (8). HeLa cells were used as p16-positive control cells. Cultured synovial fibroblasts were detached with EDTA and stained with anti–HLA–DR (BD PharMingen, Basel, Switzerland) and anti–Thy-1 (clone ASO2; Dianova, Hamburg, Germany). Cells were analyzed on a FACSCalibur flow cytometer and data were processed using CellQuest software (Becton Dickinson, San Jose, CA). For immunohistochemistry analysis, tissue sections were dewaxed in xylol and rehydrated in decreasing concen- 2070 CONCISE COMMUNICATIONS Figure 1. Expression of p16 by immunohistochemistry. Only limited p16 expression occurred in osteoarthritis (OA) synovium, but strong expression was observed in uterus glands (positive control). Expression of p16 was detected in the synovial sublining of rheumatoid arthritis patients (RA1) as well as in the lining layer in these patients (RA2) (original magnification ⫻ 100 for OA; ⫻ 200 for RA1; ⫻ 400 for uterus and RA2). trations of ethanol, pretreated by microwave heating in 0.01M citrate buffer (pH 6.0), and kept at 70°C for 30 minutes in a heat incubator for antigen retrieval. Slides were blocked at room temperature with blocking solutions A and B (Vector, Burlingame, CA), and afterwards with 2% horse serum in 4% nonfat milk/Tris HCl (0.1M, pH 7.6). Primary anti-p16 antibodies (clone G175-1239; diluted 1:100, final concentration 5 g/ml) (BD PharMingen) were applied at 4°C overnight. Mouse isotype-matched IgG sera were used as negative controls. The streptavidin–biotin detection system was used for amplification of the signal, and nitroblue tetrazolium/BCIP (Roche, Rotkreuz, Switzerland) served as color reagent. Tissue sections from normal uterus and pancreas were used as positive controls. For each patient, the percentage of positive cells was evaluated on at least 10 high-power fields (400⫻ magnification). All immunohistochemical reactions were repeated at least twice. To determine the cell types expressing p16, parallel sections of synovial tissue specimens were stained with antibodies against CD68 (dilution 1:60, final concentration 6 g/ml) (Dako, Glostrup, Denmark). Specimens from SCID mice were analyzed for the proliferation marker Ki67 with anti-Ki67 antibodies (dilution 1:100, final concentration 1 g/ml) (Dako). Incubation was performed overnight at 4°C. To amplify the signal, for the anti-CD68 and anti-Ki67 antibodies, the same streptavidin–biotin detection system was applied. In addition, SCID mouse sections were investigated with rabbit anti-active caspase 3 antibodies (dilution 1:100, final concentration 0.5 g/ml) (Cell Signaling Technology [Frankfurt, Germany], distributed by Bioconcept, [Allschwil, Switzerland]) using microwave pretreatment, the streptavidin–biotin detection system, and diaminobenzidine as color reagent (Vector). Tissue sections from juvenile thymus, breast carcinoma, and a neurologic tumor were used as positive controls. Immunofluorescence was also used for detection of p16INK4a. RASF (n ⫽ 10) or NSF (n ⫽ 1) from passages 3–7, as well as HeLa cells, were cultured on chamber slides (Labtec II; Nunc, Basel, Switzerland) and fixed with methanol/acetone (1:1) for 10 minutes at ⫺20°C. After rehydration in buffer (0.1M Tris HCl [pH 7.6]), slides were blocked with 2% horse serum in 4% nonfat milk. Slides were incubated for 30 minutes with the above-mentioned anti-p16 antibodies (dilution 1:500, final concentration 1 g/ml). Mouse isotype-matched IgG served as a negative control. For detection, Cy3-conjugated sheep anti-mouse serum (dilution 1:1,000, final concentration 0.14 g/ml) (Dianova, Hamburg, Germany) was applied for 30 minutes. After mounting, slides were analyzed with a Zeiss immunofluorescence microscope and positive cells were counted. For quantification of p16 mRNA by real-time PCR, CONCISE COMMUNICATIONS 2071 Figure 2. A, Expression of p16 in the SCID mouse coimplantation model of rheumatoid arthritis (RA). Limited cartilage invasion of normal synovial fibroblasts (NSF) and only few p16-positive cells were detected. In RASF, p16 was induced at sites of cartilage invasion, since in vitro almost all of the same cells were p16 negative (magnification ⫻400). B, Quantification of p16-positive cells at sites of cartilage invasion. Values are the mean and SEM. The expression of p16 was significantly higher in RASF than in NSF (P ⬍ 0.05 by Mann-Whitney U test). RNA was extracted from RASF (n ⫽ 8), NSF (n ⫽ 1), and HeLa cells using the RNA Miniprep Kit (Stratagene Europe, Amsterdam, The Netherlands), with DNase treatment. After reverse transcription (RT) (MultiScribe; PE Applied Biosys- tems, Rotkreuz, Switzerland), the generated complementary DNA was amplified by quantitative real-time PCR using specific primers and a TAMRA/FAM label. Primers and probe for p16 were checked for specificity by GenBank analysis. 2072 Their sequences were as follows: forward primer 5⬘-CCAACG-CAC-CGA-ATA-GTT-ACG-3⬘, reverse primer 5⬘GGG-CGC-TGC-CCA-TCA-3⬘, probe 5⬘-CAT-GAC-CTGGAT-CGG-CCT-CCG-A-3⬘. Expression of 18S ribosomal RNA using predeveloped primer/probes (PE Applied Biosystems) served as internal standard. DNA contamination was evaluated by using the mRNA sample (non-RT control) as reaction template. SCID mice were obtained from Charles River (Sulzfeld, Germany) and kept permanently under sterile conditions. Implantation of RASF (n ⫽ 5 patients, 20 animals) and NSF (n ⫽ 1 patient, 9 animals) together with normal human cartilage was performed as previously described (9). After 60 days, mice were killed, and the implants fixed in 4% buffered formalin and embedded in paraffin according to standard procedures. Paraffin-embedded sections were stained with hematoxylin and eosin or analyzed for expression of p16 by immunohistochemistry. Invasion into cartilage was quantified according to a semiquantitative score ranging from 0 to 4, referring to the number of invading cells and the number of affected cartilage sites. For statistical analysis, the Mann-Whitney U test was used. P values less than 0.05 were considered significant. Data were expressed as the mean ⫾ SEM. In the experiments using immunohistochemistry and specific anti-p16 antibodies, p16INK4a was found to be expressed in the synovial lining as well as in the sublining layer of RA synovial tissues (Figure 1). No p16INK4a staining occurred in normal synovium (results not shown), and there was only limited expression in OA synovial tissues. A mean ⫾ SEM of 6.5 ⫾ 2.0% of all cells in RA synovial tissue expressed p16INK4a, and this expression was significantly increased when compared with OA and normal synovial tissues (combined mean ⫾ SEM 0.25 ⫾ 0.25%; P ⫽ 0.014). Moreover, in a subgroup of patients with RA (3 of 13), higher p16INK4a expression, ranging from 14% to 23%, was detected. However, the staining patterns of p16 and CD68 were different. In some regions CD68 and p16 colocalized, whereas in others CD68negative areas were clearly positive for p16, indicating that CD68-negative fibroblast-like cells also expressed p16. In vitro, ⬎98% of the investigated synovial cells were positive for the fibroblast marker Thy-1, and ⬍1% stained positive for type II major histocompatibility complex molecules. As determined by immunofluorescence, the constitutive expression of p16INK4a protein was 6 ⫾ 0.5% positive cells in untreated RASF and 4% in NSF, whereas all HeLa cells exhibited staining for p16INK4a (results not shown). Accordingly, the levels of expression of p16INK4a mRNA as quantified by real-time PCR were 100 times lower in RASF than in HeLa cells. Cultured RASF from 5 patients, showing a mean level of 6% p16-positive cells, as well as NSF from 1 patient were engrafted under the renal capsule of SCID mice. In accordance with our previous findings (9), RASF invaded into the coimplanted cartilage significantly more strongly than did NSF (mean ⫾ SEM invasion score 3.0 ⫾ 0.18 for RASF, 1.2 ⫾ 0.18 for NSF; P ⬍ 0.01). Most intriguingly, RASF expressed the tumor suppressor protein p16 in 40% of the cells at sites of cartilage invasion (Figure 2A). Implanted NSF demonstrated CONCISE COMMUNICATIONS only minimal cartilage invasion, and ⬍2% of the cells adjacent to the cartilage were p16 positive (Figure 2A). In addition, parallel SCID mouse sections were immunohistochemically stained for the proliferation marker Ki67 and for the cleaved fragment of caspase 3, indicating apoptosis. In both staining reactions, only negligible signals were detected (results not shown), suggesting neither proliferation nor the occurrence of apoptosis. Of note, control tissues were positive for the determined markers. The present study reveals that p16 is induced in vivo in RASF at sites of cartilage invasion in the SCID mouse coimplantation model of RA. The in vivo induction mechanism is as yet unclear, but in vitro, Taniguchi et al (5) demonstrated induction of p16 in RASF by ionizing irradiation, low serum concentration, or sensescence. They proposed a novel treatment of RA, since in rat adjuvant arthritis and mouse collageninduced arthritis they could reduce synovial hyperplasia and mononuclear cell infiltration by gene transfer of p16 (5,6). Herein we report that the cartilage invasion process appears to be associated with the expression of p16. We suggest that p16 could mediate arrest of the cell cycle at sites of cartilage invasion, since the cells were also negative for the proliferation marker Ki67. This notion is supported by the results of investigations by Jung et al (10) demonstrating low proliferation in human colorectal adenocarcinomas at sites of tumor invasion, in association with the expression of p16. Furthermore, in tumor cells the transfection of p16 also resulted in apoptosis (11). However, in our in vivo study the expression of p16 at sites of invasion was not correlated with the detection of apoptotic cells. This result is in accordance with the findings of other studies (5) demonstrating that in vitro p16 gene transfer of RASF inhibited only the cell cycle, but did not effect apoptosis. The finding that p16 is expressed in RA tissues is in contrast with the results of Taniguchi et al (5), who reported no p16 expression in 3 RA tissues, studied using Western blot analysis. However, in the present study, immunohistochemistry analysis clearly showed positive staining for p16 in ⬃6% of the cells. Therefore, we hypothesize that in the study by Taniguchi and colleagues, the 3 RA samples investigated might not be representative for the expression of p16 in all subsets of RA tissues, at least in samples derived from Europe. In summary, we have shown that p16 was induced at sites of cartilage invasion, most likely mediating cell cycle arrest, but not apoptosis. From these data we propose a role for the tumor suppressor protein p16 in RA, specifically in the process of cartilage invasion. We assume that p16-expressing and low-proliferating RASF, which have been shown previously to be positive for the apoptosis inhibitor sentrin (12) and negative for the tumor suppressor PTEN (13) and to strongly express matrix-degrading enzymes (14), represent a phenotype associated with the arrest of the cell cycle and thereby maintain the invasive phenotype of cells mediating joint destruction in RA. We thank Maria Comazzi and Ferenc Pataky for their excellent technical assistance, and Diego Kyburz and Janine Rethage for help in the FACS analysis. Drs. Kuchen and R̂ihoŝková’s work was supported by the EMDO Foundation. Dr. Seemayer’s work was supported by the Swiss National Science Foundation and the EMDO Foundation. CONCISE COMMUNICATIONS 2073 Peter Kuenzler, MSc Stefan Kuchen, MD Veronika Řihošková, MSc Beat A. Michel, MD Renate E. Gay, MD Michel Neidhart, PhD Steffen Gay, MD University Hospital Center of Experimental Rheumatology Zurich, Switzerland Christian A. Seemayer, MD University Hospital Center of Experimental Rheumatology Zurich, Switzerland and University Hospital Institut of Pathology Basel, Switzerland 1. Gay S, Gay RE, Koopman WJ. Molecular and cellular mechanisms of joint destruction in rheumatoid arthritis: two cellular mechanisms explain joint destruction? Ann Rheum Dis 1993;52 Suppl 1:S39–47. 2. Muller-Ladner U, Gay RE, Gay S. Activation of synoviocytes. Curr Opin Rheumatol 2000;12:186–94. 3. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993;366:704–7. 4. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 1994;368:753–6. 5. Taniguchi K, Kohsaka H, Inoue N, Terada Y, Ito H, Hirokawa K, et al. Induction of the p16INK4a senescence gene as a new therapeutic strategy for the treatment of rheumatoid arthritis. Nat Med 1999;5:760–7. 6. Nasu K, Kohsaka H, Nonomura Y, Terada Y, Ito H, Hirokawa K, 7. 8. 9. 10. 11. 12. 13. 14. et al. Adenoviral transfer of cyclin-dependent kinase inhibitor genes suppresses collagen-induced arthritis in mice. J Immunol 2000;165:7246–52. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315–24. Pap T, van der Laan WH, Aupperle KR, Gay RE, Verheijen JH, Firestein GS, et al. Modulation of fibroblast-mediated cartilage degradation by articular chondrocytes in rheumatoid arthritis. Arthritis Rheum 2000;43:2531–6. Muller-Ladner U, Kriegsmann J, Franklin BN, Matsumoto S, Geiler T, Gay RE, et al. Synovial fibroblasts of patients with rheumatoid arthritis attach to and invade normal human cartilage when engrafted into SCID mice. Am J Pathol 1996;149:1607–15. Jung A, Schrauder M, Oswald U, Knoll C, Sellberg P, Palmqvist R, et al. The invasion front of human colorectal adenocarcinomas shows co-localization of nuclear beta-catenin, cyclin D1, and p16INK4A and is a region of low proliferation. Am J Pathol 2001;159:1613–7. Katsuda K, Kataoka M, Uno F, Murakami T, Kondo T, Roth JA, et al. Activation of caspase-3 and cleavage of Rb are associated with p16-mediated apoptosis in human non-small cell lung cancer cells. Oncogene 2002;21:2108–13. Franz JK, Pap T, Hummel KM, Nawrath M, Aicher WK, Shigeyama Y, et al. Expression of sentrin, a novel antiapoptotic molecule, at sites of synovial invasion in rheumatoid arthritis. Arthritis Rheum 2000;43:599–607. Pap T, Franz JK, Hummel KM, Jeisy E, Gay R, Gay S. Activation of synovial fibroblasts in rheumatoid arthritis: lack of expression of the tumour suppressor PTEN at sites of invasive growth and destruction. Arthritis Res 2000;2:59–64. Pap T, Shigeyama Y, Kuchen S, Fernihough JK, Simmen B, Gay RE, et al. Differential expression pattern of membrane-type matrix metalloproteinases in rheumatoid arthritis. Arthritis Rheum 2000;43:1226–32.